A Report on Chelating Therapy and Patient Compliance by Determination of Serum Ferritin Levels in 243 Thalassemia Major Patients

Mohamad Pedram; Khodamorad Zandian; Bijan Keikhaie; Reza Akramipour; Akram Hashemi; Fatemeh Ghahfarokhi; Mohamad Soudagar

Journal of Comprehensive Pediatrics

Accepted Manuscripts Current Issue All Issues In Press Search

Journal Information Boards and Committees Indexing and Listing Sources Publication Ethics and Publication Malpractice Statement Support Journal Metrics Reviewer and AE Registration Form Contact Us Open Peer Review (OPR)

APC

Authors Guide Submit Manuscript

A Report on Chelating Therapy and Patient Compliance by Determination of Serum Ferritin Levels in 243 Thalassemia Major Patients

Author(s):

Mohamad Pedram¹,

Khodamorad Zandian^2,*,

Bijan Keikhaie¹,

Reza Akramipour¹,

Akram Hashemi¹,

Fatemeh Kianpour Ghahfarokhi¹,

Mohamad Soudagar¹

1Research Center for Thalassemia & Hemoglobinopathies, Jondishapour University, Iran

2Research Center for Thalassemia & Hemoglobinopathies, Jondishapour University, [email protected], Iran

Journal of Comprehensive Pediatrics:Vol. 2, issue 2; 65-69

Published online:Dec 31, 2010

Article type:Research Article

Received:Oct 01, 2009

Accepted:Jan 01, 2010

How to Cite:Pedram M, Zandian K, Keikhaie B, Akramipour R, Hashemi A, et al. A Report on Chelating Therapy and Patient Compliance by Determination of Serum Ferritin Levels in 243 Thalassemia Major Patients. J Compr Ped. 2010;2(2):. doi:

Abstract

Background and Aim: This cross- sectional study was designed for determining the monthly serial serum ferritin levels and adequacy of Desferrioxamine usage in β-thalassemia major patients for roughly estimated outcome of compliance by subcutaneous Desferrioxamine chelation therapy.

Materials and Methods: In this study, 243 patients suffering from β-thalassemia major who had referred to the Thalassemia center affiliated to Ahvaz Jundishapur of Medical Sciences University, were investigated carefully and assessed for monthly serial serum ferritin levels. They received regular blood transfusions and follow ups were done in one year (Sept 1998 - Sept 1999). Ferritin levels were measured by IRMA technique. Patients with a high serum ferritin level due to false positive causes were excluded from this study. Iron chelating treatment was started when serum ferritin levels was about 1000-1500 µg/lit. This usually occurred after the first 10-20 transfusions (nearly 3 years of age). It was prescribed for regular daily adjusted dosage (subcutaneous, 25-50 mg/kg/24hr) over 8-12 hrs for administration at home. It was infused via a thin needle inserted subcutaneously and connected by an infusion line to a portable battery electrical infusion device. In selected heavily iron-load subjects, it was given via IV route in dose of 50 mg/kg/24hr, by short hospital admissions.

Results: Compliance adherence was observed only in 46 patients (18.2%, first group) with desirable serum ferritin levels less than 2000 µg/lit. Improved compliance adhesion was achieved in 78 patients (31.3%, second group) with unsatisfactory serum ferritin levels between 2000- 4000 µg/lit. Even though in this group the compliance adherence could be improved by close surveillance of Desferrioxamine infusions and intimate scrutiny by psychology intervention and social workers activity. In 119 patients (48.8%, third group) compliance was not achieved with serum ferritin levels more than 4000 µg/lit and more. These high risk patients were kept under evaluation by medical care through IV Desferrioxamine infusion and other medical treatments as needed and collaboration of social worker and psychology intervention.

Conclusion: Compliance adherence was achieved only in 18.2% of patients (first group) and compliance adherence was improved by close surveillance of Desferrioxamine infusions and psychology intervention and social workers activity in 31.3% (second group). Despite every day encouragement, compliance was not achieved in 48.8% (third group). Overall outcome was poor.

Keywords

Desferroxamine

Major thalassemia

Serum ferritin

Full Text

Full text is available in PDF

Combined Therapy with Desferal and Deferioprone in Improvement of Heart Function in Thalassemic Patients

Noormohammad Noori,

Peyman Eshghi,

Fatemeh shahramian

Noori N, Eshghi P, shahramian F. Combined Therapy with Desferal and Deferioprone in Improvement of Heart Function in Thalassemic Patients. Zahedan J Res Med Sci. 2010;11(4):e94362. doi:

19

Jan

2012

Hearing status of thalassemic patients treated with dessfroxamin

Majid Ashrafi,

Ali Mohammadzadeh

Ashrafi M, Mohammadzadeh A. Hearing status of thalassemic patients treated with dessfroxamin. J Kermanshah Univ Med Sci. 2012;15(5):e79024. doi:

13

Sep

2010

Dental health and dental treatment needs in patients with thalassemia major

Marieh Honarmand,

Narjes Amiri tehrani,

Leila Farhad-Mollashahi

Honarmand M, Amiri tehrani N, Farhad-Mollashahi L. Dental health and dental treatment needs in patients with thalassemia major. Zahedan J Res Med Sci. 2010;12(3):e94300. doi:

30

Apr

2008

Evaluation of Endocrine Disorders in Patients with Thalassemia Major

F Najafipour

Najafipour F. Evaluation of Endocrine Disorders in Patients with Thalassemia Major. Int J Endocrinol Metab. 2008;6(2):. doi:

28

Oct

2017

Comparison of Beta-2 Microglobulin Level and Some Variables Between Thalassemia Major Patients Who Treated by Desferal and Control Group

Mandana Zafari,

Azar Aghamohammady

Zafari M, Aghamohammady A. Comparison of Beta-2 Microglobulin Level and Some Variables Between Thalassemia Major Patients Who Treated by Desferal and Control Group. Zahedan J Res Med Sci. 2017;19(10):e11538. doi: https://doi.org/10.5812/zjrms.11538

Import into EndNote Import into BibTex

Share on

Comments

Number of Comments:0

Cited by

Scopus by DOI: 0
Last Update: 1 week ago
Scopus by Title: 0
Last Update: 1 week ago
Scopus by Title (Ref): 9
Last Update: 1 week ago
CrossRef: 0
Last Update: 2 days ago

Metrics

Ordering Reprints

Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC

Search Relations

Author(s):

Mohamad Pedram:[PubMed][Scholar]
Khodamorad Zandian:[PubMed][Scholar]
Bijan Keikhaie:[PubMed][Scholar]
Reza Akramipour:[PubMed][Scholar]
Akram Hashemi:[PubMed][Scholar]
Fatemeh Ghahfarokhi:[PubMed][Scholar]
Mohamad Soudagar:[PubMed][Scholar]

Outlines

A Report on Chelating Therapy and Patient Compliance by Determination of Serum Ferritin Levels in 243 Thalassemia Major Patients

Abstract

Full Text

Similar Articles

Combined Therapy with Desferal and Deferioprone in Improvement of Heart Function in Thalassemic Patients

Hearing status of thalassemic patients treated with dessfroxamin

Dental health and dental treatment needs in patients with thalassemia major

Evaluation of Endocrine Disorders in Patients with Thalassemia Major

Comparison of Beta-2 Microglobulin Level and Some Variables Between Thalassemia Major Patients Who Treated by Desferal and Control Group

Last Update: 1 week ago

Last Update: 1 week ago

Last Update: 1 week ago

Last Update: 2 days ago